Indeed, corticosteroids (13), Janus kinase (JAK) inhibitors that block cytokine signaling pathways such as Ruxolitinib (Ruxo) (14–21) or Baricitinib (22–25), the IL-6 antibody Tocilizumab (26–28) or the IL-1 receptor antagonist Anakinra (29, 30) were found to improve outcome in hospitalized COVID-19 patients. The gene discussed is IL6; the disease is COVID-19.